Asymptotic safety in the dark

We explore the Renormalization Group flow of massive uncharged fermions -- a candidate for dark matter -- coupled to a scalar field through a Higgs portal. We find that fermionic fluctuations can lower the bound on the scalar mass that arises from vacuum stability. Further, we discuss that despite the perturbative nonrenormalizability of the model, it could be ultraviolet complete at an asymptotically safe fixed point. In our approximation, this simple model exhibits two mechanisms for asymptotic safety: a balance of fermionic and bosonic fluctuations generates a fixed point in the scalar self-interaction; asymptotic safety in the portal coupling is triggered through a balance of canonical scaling and quantum fluctuations. As a consequence of asymptotic safety in the dark sector, the low-energy value of the portal coupling could become a function of the dark fermion mass and the scalar mass, thereby reducing the viable parameter space of the model.Comment: 16 pages plus appendix; 5 figure

From red to blue shift: switching the binding affinity from the acceptor to the donor end by increasing the π-bridge in push–pull chromophores with coordinative ends

A series of homologous push–pull compounds, in which identical donor (a dimethylamino) and acceptor (a malonate ester) functionalities endcap crescent PPV fragments, exhibit striking differences in their supramolecular recognition of cations acting as Lewis acids. The shorter conjugated compound (one phenyl ring) coordinates a wide variety of lanthanide cations (Eu3+, Yb3+ and Er3+) in MeCN solutions to the 1,3-dicarbonyl acceptor end, resulting in an overall supramolecular polarization of the system (red shift of the intramolecular charge-transfer ICT band). With the “hard” cation Sc3+, recognition switches to the tertiary amine donor end, turning the conjugated system from D–π–A to A–π–A, and resulting in a blue shift of the ICT band upon complexation. Interestingly, increasing the conjugation by means of the insertion of sequential p-phenylenevinylene units into the ligand results in coordination to the donor end regardless of cation “hardness” (Sc3+, Eu3+ and Er3+), suggesting a relative change in the nucleophilicity of the two coordinating ends when increasing the length of the conjugated π-bridge. Such a hypothesis is supported by quantum chemical calculations on the ligands and subsequent atomic charges determination using two independent approaches (QTAIM and CHelpG). The characterization of the thermodynamic stabilities and the dimensionalities of the ligand–cation complexes in solution reveals striking differences from case to case, yet increasing affinities (from log Kav = 2.5 to log Kav = 4.9) are recorded with the increase of the π-conjugated bridge

A chiroptical molecular sensor for ferrocene

A chiral molecular sensor is used to recognize ferrocene, with the chiroptical readout used selectively in the presence of competing analytes

Bottomonium suppression in an open quantum system using the quantum trajectories method

We solve the Lindblad equation describing the Brownian motion of a Coulombic heavy quark-antiquark pair in a strongly coupled quark-gluon plasma using the highly efficient Monte Carlo wave-function method. The Lindblad equation has been derived in the framework of pNRQCD and fully accounts for the quantum and non-Abelian nature of the system. The hydrodynamics of the plasma is realistically implemented through a 3+1D dissipative hydrodynamics code. We compute the bottomonium nuclear modification factor and compare with the most recent LHC data. The computation does not rely on any free parameter, as it depends on two transport coefficients that have been evaluated independently in lattice QCD. Our final results, which include late-time feed down of excited states, agree well with the available data from LHC 5.02 TeV PbPb collisions.Comment: 42 pages, 18 figure

Heavy quarkonium dynamics at next-to-leading order in the binding energy over temperature

Using the potential non-relativistic quantum chromodynamics (pNRQCD) effective field theory, we derive a Lindblad equation for the evolution of the heavy-quarkonium reduced density matrix that is accurate to next-to-leading order (NLO) in the ratio of the binding energy of the state to the temperature of the medium. The resulting NLO Lindblad equation can be used to more reliably describe heavy-quarkonium evolution in the quark-gluon plasma at low temperatures compared to the leading-order truncation. For phenomenological application, we numerically solve the resulting NLO Lindblad equation using the quantum trajectories algorithm. To achieve this, we map the solution of the three-dimensional Lindblad equation to the solution of an ensemble of one-dimensional Schr\"odinger evolutions with Monte-Carlo sampled quantum jumps. Averaging over the Monte-Carlo sampled quantum jumps, we obtain the solution to the NLO Lindblad equation without truncation in the angular momentum quantum number of the states considered. We also consider the evolution of the system using only the complex effective Hamiltonian without stochastic jumps and find that this provides a reliable approximation for the ground state survival probability at LO and NLO. Finally, we make comparisons with our prior leading-order pNRQCD results and experimental data available from the ATLAS, ALICE, and CMS collaborations.Comment: 40 pages, 8 figure

Loss of Androgen Receptor-Dependent Growth Suppression by Prostate Cancer Cells Can Occur Independently from Acquiring Oncogenic Addiction to Androgen Receptor Signaling

The conversion of androgen receptor (AR) signaling as a mechanism of growth suppression of normal prostate epithelial cells to that of growth stimulation in prostate cancer cells is often associated with AR mutation, amplification and over-expression. Thus, down-regulation of AR signaling is commonly therapeutic for prostate cancer. The E006AA cell line was established from a hormone naïve, localized prostate cancer. E006AA cells are genetically aneuploid and grow equally well when xenografted into either intact or castrated male NOG but not nude mice. These cells exhibit: 1) X chromosome duplication and AR gene amplification, although paradoxically not coupled with increased AR expression, and 2) somatic, dominant-negative Serine-599-Glycine loss-of-function mutation within the dimerization surface of the DNA binding domain of the AR gene. No effect on the growth of E006AA cells is observed using targeted knockdown of endogenous mutant AR, ectopic expression of wild-type AR, or treatment with androgens or anti-androgens. E006AA cells represent a prototype for a newly identified subtype of prostate cancer cells that exhibit a dominant-negative AR loss-of-function in a hormonally naïve patient. Such loss-of-function eliminates AR-mediated growth suppression normally induced by normal physiological levels of androgens, thus producing a selective growth advantage for these malignant cells in hormonally naïve patients. These data highlight that loss of AR-mediated growth suppression is an independent process, and that, without additional changes, is insufficient for acquiring oncogene addiction to AR signaling. Thus, patients with prostate cancer cells harboring such AR loss-of-function mutations will not benefit from aggressive hormone or anti-AR therapies even though they express AR protein

Human α2β1HI CD133+VE epithelial prostate stem cells express low levels of active androgen receptor

Stem cells are thought to be the cell of origin in malignant transformation in many tissues, but their role in human prostate carcinogenesis continues to be debated. One of the conflicts with this model is that cancer stem cells have been described to lack androgen receptor (AR) expression, which is of established importance in prostate cancer initiation and progression. We re-examined the expression patterns of AR within adult prostate epithelial differentiation using an optimised sensitive and specific approach examining transcript, protein and AR regulated gene expression. Highly enriched populations were isolated consisting of stem (α(2)β(1)(HI) CD133(+VE)), transiently amplifying (α(2)β(1)(HI) CD133(-VE)) and terminally differentiated (α(2)β(1)(LOW) CD133(-VE)) cells. AR transcript and protein expression was confirmed in α(2)β(1)(HI) CD133(+VE) and CD133(-VE) progenitor cells. Flow cytometry confirmed that median (±SD) fraction of cells expressing AR were 77% (±6%) in α(2)β(1)(HI) CD133(+VE) stem cells and 68% (±12%) in α(2)β(1)(HI) CD133(-VE) transiently amplifying cells. However, 3-fold lower levels of total AR protein expression (peak and median immunofluorescence) were present in α(2)β(1)(HI) CD133(+VE) stem cells compared with differentiated cells. This finding was confirmed with dual immunostaining of prostate sections for AR and CD133, which again demonstrated low levels of AR within basal CD133(+VE) cells. Activity of the AR was confirmed in prostate progenitor cells by the expression of low levels of the AR regulated genes PSA, KLK2 and TMPRSS2. The confirmation of AR expression in prostate progenitor cells allows integration of the cancer stem cell theory with the established models of prostate cancer initiation based on a functional AR. Further study of specific AR functions in prostate stem and differentiated cells may highlight novel mechanisms of prostate homeostasis and insights into tumourigenesis

The p75 Neurotrophin Receptor Promotes Amyloid- (1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo

Oligomeric forms of amyloid-beta (Abeta) are thought to play a causal role in Alzheimer's disease (AD), and the p75 neurotrophin receptor (p75(NTR)) has been implicated in Abeta-induced neurodegeneration. To further define the functions of p75(NTR) in AD, we examined the interaction of oligomeric Abeta(1-42) with p75(NTR), and the effects of that interaction on neurite integrity in neuron cultures and in a chronic AD mouse model. Atomic force microscopy was used to ascertain the aggregated state of Abeta, and fluorescence resonance energy transfer analysis revealed that Abeta oligomers interact with the extracellular domain of p75(NTR). In vitro studies of Abeta-induced death in neuron cultures isolated from wild-type and p75(NTR-/-) mice, in which the p75(NTR) extracellular domain is deleted, showed reduced sensitivity of mutant cells to Abeta-induced cell death. Interestingly, Abeta-induced neuritic dystrophy and activation of c-Jun, a known mediator of Abeta-induced deleterious signaling, were completely prevented in p75(NTR-/-) neuron cultures. Thy1-hAPP(Lond/Swe) x p75(NTR-/-) mice exhibited significantly diminished hippocampal neuritic dystrophy and complete reversal of basal forebrain cholinergic neurite degeneration relative to those expressing wild-type p75(NTR). Abeta levels were not affected, suggesting that removal of p75(NTR) extracellular domain reduced the ability of excess Abeta to promote neuritic degeneration. These findings indicate that although p75(NTR) likely does not mediate all Abeta effects, it does play a significant role in enabling Abeta-induced neurodegeneration in vitro and in vivo, establishing p75(NTR) as an important therapeutic target for AD

Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer Cells

Cancer stem cells (CSCs) are often characterized by the elevated expression of drug-resistance related stem-cell surface markers, such as CD133 and ABCG2. Recently, we reported that CSCs have a high level of expression of the IL-6 receptor (IL-6R). The purpose of this study was to investigate the effect of anticancer drugs on the expression of the drug resistance-related cancer stem cell markers, ABCG2, IL-6R, and CD133 in non-small cell lung cancer (NSCLC) cell lines. A549, H460, and H23 NSCLC cell lines were treated with the anticancer drugs 5-fluorouracil (5-FU; 25 µg/ml) and methotrexate (MTX; 50 µg/ml), and the expression of putative CSC markers was analyzed by fluorescent activated cell sorter (FACS) and the gene expression level of abcg2, il-6r and cd133 by reverse transcriptasepolymerase chain reaction (RT-PCR). We found that the fraction of ABCG2-positive(+) cells was significantly increased by treatment with both 5-FU and MTX in NSCLC cells, and the elevation of abcg2, il-6r and cd133 expressions in response to these drugs was also confirmed using RT-PCR. Also, the number of IL-6R(+) cells was increased by MTX in the 3 cell lines mentioned and increased by 5-FU in the H460 cell line. The number of CD133(+) cells was also significantly increased by both 5-FU and MTX treatment in all of the cell lines tested. These results indicate that 5-FU and MTX considerably enhance the expression of drug-resistance related CSC markers in NSCLC cell lines. Thus, we suggest that antimetabolite cancer drugs, such as 5-FU and MTX, can lead to the propagation of CSCs through altering the expression of CSC markers